Cargando…

A bispecific monoclonal antibody against methotrexate and a human tumour associated antigen augments cytotoxicity of methotrexate-carrier conjugate.

A bispecific monoclonal antibody, reactive with methotrexate (MTX) and a tumour associated antigen (gp72) has been produced by fusing spleen cells from MTX immunised mice with 791T/36/3 (anti-gp72) hybridoma. The hybrid antibody was purified from anti-MTX and anti-gp72 antibodies present in the hybr...

Descripción completa

Detalles Bibliográficos
Autores principales: Pimm, M. V., Robins, R. A., Embleton, M. J., Jacobs, E., Markham, A. J., Charleston, A., Baldwin, R. W.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1990
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971384/
https://www.ncbi.nlm.nih.gov/pubmed/2331436
_version_ 1782134898346164224
author Pimm, M. V.
Robins, R. A.
Embleton, M. J.
Jacobs, E.
Markham, A. J.
Charleston, A.
Baldwin, R. W.
author_facet Pimm, M. V.
Robins, R. A.
Embleton, M. J.
Jacobs, E.
Markham, A. J.
Charleston, A.
Baldwin, R. W.
author_sort Pimm, M. V.
collection PubMed
description A bispecific monoclonal antibody, reactive with methotrexate (MTX) and a tumour associated antigen (gp72) has been produced by fusing spleen cells from MTX immunised mice with 791T/36/3 (anti-gp72) hybridoma. The hybrid antibody was purified from anti-MTX and anti-gp72 antibodies present in the hybridoma culture supernatant by combinations of affinity chromatography on a MTX-agarose immunoabsorbent and stepwise acid elution from Sepharose-Protein A. A particular feature of the present antibody is that it reacts with conjugated MTX; this would allow in vivo targeting of conjugates, increasing many fold the number of molecules of drug carried or localising to pre-targeted antibody. Dual binding between tumour cell surface antigen and MTX was demonstrated by the ability of the hybrid antibody to bridge between tumour cells and MTX as MTX-HSA conjugate, reaction here being detected by flow cytofluorimetry. Purified hybrid antibody specifically enhanced the in vitro cytotoxicity of MTX-HSA for gp72 positive tumour cells.
format Text
id pubmed-1971384
institution National Center for Biotechnology Information
language English
publishDate 1990
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19713842009-09-10 A bispecific monoclonal antibody against methotrexate and a human tumour associated antigen augments cytotoxicity of methotrexate-carrier conjugate. Pimm, M. V. Robins, R. A. Embleton, M. J. Jacobs, E. Markham, A. J. Charleston, A. Baldwin, R. W. Br J Cancer Research Article A bispecific monoclonal antibody, reactive with methotrexate (MTX) and a tumour associated antigen (gp72) has been produced by fusing spleen cells from MTX immunised mice with 791T/36/3 (anti-gp72) hybridoma. The hybrid antibody was purified from anti-MTX and anti-gp72 antibodies present in the hybridoma culture supernatant by combinations of affinity chromatography on a MTX-agarose immunoabsorbent and stepwise acid elution from Sepharose-Protein A. A particular feature of the present antibody is that it reacts with conjugated MTX; this would allow in vivo targeting of conjugates, increasing many fold the number of molecules of drug carried or localising to pre-targeted antibody. Dual binding between tumour cell surface antigen and MTX was demonstrated by the ability of the hybrid antibody to bridge between tumour cells and MTX as MTX-HSA conjugate, reaction here being detected by flow cytofluorimetry. Purified hybrid antibody specifically enhanced the in vitro cytotoxicity of MTX-HSA for gp72 positive tumour cells. Nature Publishing Group 1990-04 /pmc/articles/PMC1971384/ /pubmed/2331436 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Pimm, M. V.
Robins, R. A.
Embleton, M. J.
Jacobs, E.
Markham, A. J.
Charleston, A.
Baldwin, R. W.
A bispecific monoclonal antibody against methotrexate and a human tumour associated antigen augments cytotoxicity of methotrexate-carrier conjugate.
title A bispecific monoclonal antibody against methotrexate and a human tumour associated antigen augments cytotoxicity of methotrexate-carrier conjugate.
title_full A bispecific monoclonal antibody against methotrexate and a human tumour associated antigen augments cytotoxicity of methotrexate-carrier conjugate.
title_fullStr A bispecific monoclonal antibody against methotrexate and a human tumour associated antigen augments cytotoxicity of methotrexate-carrier conjugate.
title_full_unstemmed A bispecific monoclonal antibody against methotrexate and a human tumour associated antigen augments cytotoxicity of methotrexate-carrier conjugate.
title_short A bispecific monoclonal antibody against methotrexate and a human tumour associated antigen augments cytotoxicity of methotrexate-carrier conjugate.
title_sort bispecific monoclonal antibody against methotrexate and a human tumour associated antigen augments cytotoxicity of methotrexate-carrier conjugate.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971384/
https://www.ncbi.nlm.nih.gov/pubmed/2331436
work_keys_str_mv AT pimmmv abispecificmonoclonalantibodyagainstmethotrexateandahumantumourassociatedantigenaugmentscytotoxicityofmethotrexatecarrierconjugate
AT robinsra abispecificmonoclonalantibodyagainstmethotrexateandahumantumourassociatedantigenaugmentscytotoxicityofmethotrexatecarrierconjugate
AT embletonmj abispecificmonoclonalantibodyagainstmethotrexateandahumantumourassociatedantigenaugmentscytotoxicityofmethotrexatecarrierconjugate
AT jacobse abispecificmonoclonalantibodyagainstmethotrexateandahumantumourassociatedantigenaugmentscytotoxicityofmethotrexatecarrierconjugate
AT markhamaj abispecificmonoclonalantibodyagainstmethotrexateandahumantumourassociatedantigenaugmentscytotoxicityofmethotrexatecarrierconjugate
AT charlestona abispecificmonoclonalantibodyagainstmethotrexateandahumantumourassociatedantigenaugmentscytotoxicityofmethotrexatecarrierconjugate
AT baldwinrw abispecificmonoclonalantibodyagainstmethotrexateandahumantumourassociatedantigenaugmentscytotoxicityofmethotrexatecarrierconjugate
AT pimmmv bispecificmonoclonalantibodyagainstmethotrexateandahumantumourassociatedantigenaugmentscytotoxicityofmethotrexatecarrierconjugate
AT robinsra bispecificmonoclonalantibodyagainstmethotrexateandahumantumourassociatedantigenaugmentscytotoxicityofmethotrexatecarrierconjugate
AT embletonmj bispecificmonoclonalantibodyagainstmethotrexateandahumantumourassociatedantigenaugmentscytotoxicityofmethotrexatecarrierconjugate
AT jacobse bispecificmonoclonalantibodyagainstmethotrexateandahumantumourassociatedantigenaugmentscytotoxicityofmethotrexatecarrierconjugate
AT markhamaj bispecificmonoclonalantibodyagainstmethotrexateandahumantumourassociatedantigenaugmentscytotoxicityofmethotrexatecarrierconjugate
AT charlestona bispecificmonoclonalantibodyagainstmethotrexateandahumantumourassociatedantigenaugmentscytotoxicityofmethotrexatecarrierconjugate
AT baldwinrw bispecificmonoclonalantibodyagainstmethotrexateandahumantumourassociatedantigenaugmentscytotoxicityofmethotrexatecarrierconjugate